GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
“Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion in Sickle Cell Disease: Results from a Phase 1/2 study.”
One oral presentation was entitled "Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion in Sickle Cell Disease: Results from a Phase 1/2 study." The presentation focused on clinical results showing effects of GMI-1070 on certain key biomarkers. Two related posters described effects of GMI-1070 on the activation state of leukocytes (white blood cells), as well as the safety and pharmacokinetics of the drug.
In addition to the clinical data in sickle cell, preclinical data using GMI-1070 in models of myeloma was also selected for an oral presentation entitled "Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy."
"We are very pleased to have the opportunity to present data on our lead compound at the ASH meeting," said Rachel King, the company's Chief Executive Officer. "We have made significant progress this year in the clinic, as well as in pre-clinical testing of GMI-1070. The data supports testing the drug in sickle cell crisis, and the Phase 2 trial is now underway. We are also encouraged by the preclinical results in myeloma, which suggest that the drug may have a novel mechanism of action for treatment of hematologic (blood-related) malignancies."
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery